帕金森病患者血浆代谢组与肠道菌群变化:聚焦咖啡因代谢
PD患者咖啡因代谢显著降低,咖啡因及其代谢物水平与运动严重程度负相关,部分PD富集菌种与咖啡因代谢物负相关。
要点
- PD患者咖啡因代谢显著低于对照(p=0.0013),咖啡因及其代谢物血清水平与运动严重程度负相关(p<0.01)。
- 靶向分析证实PD患者咖啡因、茶碱、副黄嘌呤、1,7-二甲基尿酸和5-乙酰氨基-6-氨基-3-甲基尿嘧啶水平降低,验证队列重复(p<0.05)。
- PD富集的56种菌种与咖啡因及副黄嘌呤、茶碱负相关(均p<0.05),包括Clostridium sp000435655等。
核心结论
- 研究识别出PD患者与对照相比存在微生物-咖啡因代谢相关改变。
- 发现为未来咖啡因-微生物组相互作用的功能研究提供线索。
研究设计与样本
- 多中心研究:探索队列来自台湾大学医院,验证队列来自马来亚大学医学中心。
- 探索队列行非靶向血清代谢组学(液相色谱-高分辨质谱)及咖啡因靶向代谢组学,并行宏基因组鸟枪法测序分析肠道菌群。
- 验证队列行靶向代谢组学验证咖啡因及其12种下游代谢物。
- 记录体重指数、抗帕金森病药物使用及饮食习惯(包括咖啡和茶摄入)。
主要发现
- 非靶向代谢组学共检测5,158种代谢物,其中3,131种高置信度用于分析。
- 与对照相比,PD患者有56种代谢物丰度显著升高、7种显著降低(校正p<0.05且log2倍数变化>1)。
- PD患者咖啡因代谢显著降低(p=0.0013),血清咖啡因及其代谢物水平与运动严重程度负相关(p<0.01)。
- 靶向分析证实PD患者咖啡因及茶碱、副黄嘌呤、1,7-二甲基尿酸、5-乙酰氨基-6-氨基-3-甲基尿嘧啶水平降低,验证队列重复(p<0.05)。
- 聚类分析发现PD富集的56种菌种与咖啡因及副黄嘌呤、茶碱负相关(均p<0.05), notably Clostridium sp000435655、Acetatifactor sp900066565、Oliverpabstia intestinalis、Ruminiclostridium siraeum。
关键数值与推荐
- PD患者咖啡因代谢显著低于对照(p=0.0013)。
- PD患者血清咖啡因及其代谢物水平与运动严重程度负相关(p<0.01)。
- 靶向分析PD患者咖啡因、茶碱、副黄嘌呤、1,7-二甲基尿酸、5-乙酰氨基-6-氨基-3-甲基尿嘧啶水平降低,验证队列重复(p<0.05)。
- PD富集的56种菌种与咖啡因及副黄嘌呤、茶碱负相关(均p<0.05)。
临床怎么用
- 研究提示PD患者存在咖啡因代谢降低及特定菌群改变,咖啡因代谢物水平与运动严重程度负相关。
- 发现为未来咖啡因-微生物组相互作用的功能研究提供方向。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Coffee intake is linked to a reduced risk of Parkinson disease (PD), but whether this effect is mediated by gut microbiota and metabolomic changes remains unclear. This study examines PD-associated metabolomic shifts, caffeine metabolism, and their connection to gut microbiome alterations in a multicenter study. METHODS: We conducted an untargeted serum metabolomic assay using liquid chromatography with high-resolution mass spectrometry on an exploratory cohort recruited from National Taiwan University Hospital (NTUH). A targeted metabolomic assay focusing on caffeine and its 12 downstream metabolites was conducted and validated in an independent cohort from University Malaya Medical Centre (UMMC). In the exploratory cohort, the association of each caffeine metabolite with gut microbiota changes was investigated by metagenomic shotgun sequencing. A clustering-based approach was used to correlate microbiome changes with plasma caffeine metabolite level and clinical severity. Body mass index, antiparkinsonism medication use, and dietary habits (including coffee and tea intake) were recorded. RESULTS: Sixty-three patients with PD and 54 controls from NTUH formed the exploratory cohort while 36 patients with PD and 20 controls from UMMC served as an validation cohort to replicate the plasma caffeine findings. A total of 5,158 metabolites were detected from untargeted metabolomic analysis, with 3,131 having high confidence for analysis. Compared with controls, the abundance of 56 metabolites was significantly higher and that of 7 metabolites was significantly lower (adjusted p < 0.05 and log2 fold change >1) in patients with PD. Caffeine metabolism was significantly lower in patients with PD (p = 0.0013), and serum levels of caffeine and its metabolites negatively correlated with motor severity (p < 0.01). Targeted metabolomic analysis confirmed reduced levels of caffeine and its metabolites, including theophylline, paraxanthine, 1,7-dimethyluric acid, and 5-acetylamino-6-amino-3-methyluracil, in patients with PD; these findings were replicated in the validation cohort (p < 0.05). A clustering approach found that 56 microbiome species enriched in patients with PD negatively correlated with caffeine and its metabolites paraxanthine and theophylline (both p < 0.05), notably Clostridium sp000435655, Acetatifactor sp900066565, Oliverpabstia intestinalis, and Ruminiclostridium siraeum. DISCUSSION: This study identifies PD-related changes in microbial-caffeine metabolism compared with controls. Our findings offer insights for future functional research on caffeine-microbiome interactions in PD.
引用
- Chen CC, Chiu JY, Tan AH, et al. Investigating Plasma Metabolomics and Gut Microbiota Changes Associated With Parkinson Disease: A Focus on Caffeine Metabolism. Neurology. 2025. PMID: 40273394. doi:10.1212/WNL.0000000000213592
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。